What is Fulgent Genetics Return-on-Tangible-Equity?
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Fulgent Genetics's annualized net income for the quarter that ended in Mar. 2024 was MXN-894 Mil. Fulgent Genetics's average shareholder tangible equity for the quarter that ended in Mar. 2024 was MXN16,264 Mil. Therefore, Fulgent Genetics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -5.49%.
The historical rank and industry rank for Fulgent Genetics's Return-on-Tangible-Equity or its related term are showing as below:
MEX:FLGT'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -254.33 Med: -7.64 Max: 65.72
Current: -17.09
During the past 10 years, Fulgent Genetics's highest Return-on-Tangible-Equity was 65.72%. The lowest was -254.33%. And the median was -7.64%.
MEX:FLGT's Return-on-Tangible-Equity is ranked worse than 61.11% of 198
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.175
vs MEX:FLGT: -17.09
Fulgent Genetics Return-on-Tangible-Equity Historical Data
The historical data trend for Fulgent Genetics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Fulgent Genetics's Return-on-Tangible-Equity
For the Diagnostics & Research subindustry, Fulgent Genetics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulgent Genetics's Return-on-Tangible-Equity Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2024) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Fulgent Genetics Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of Fulgent Genetics's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEX:FLGT has been successfully added to your 